

Fluconazole Prophylaxis against Fungal Colonization and Invasive Fungal Infection in Very Low Birth Weight Infants

Tushar B Parikh, Ruchi N Nanavati, *Chandrakant V Patankar, Suman Rao PN,
*Kishore Bisure, Rekha H Udani and *Preeti Mehta

From the Department of Neonatology & *Department of Microbiology, KEM Hospital and Seth GS Medical College, Mumbai 400 012, India.

Correspondence to: Dr. Tushar B Parikh, Unit 92, Staff Accommodation, P.O. Box 293, Darcy Street, Wentworthville, NSW 2145, Australia. E-mail: tbparikh@rediffmail.com

Manuscript received: September 23, 2005; Initial review completed: December 27, 2005;
Revision accepted: June 20, 2007.

Background: Fungal infections are common cause of morbidity and mortality in very low birth weight Infants **Objectives:** To evaluate the efficacy of prophylactic Fluconazole in preventing fungal colonization and invasive fungal infection in VLBW infants. **Design:** Prospective, randomized, double blind placebo controlled clinical trial. **Setting:** Tertiary level Neonatal intensive care unit. **Subjects:** 120 preterm infants with birth Weight < 1500 g. **Intervention:** Infants were randomly assigned during first three days to receive either Fluconazole or placebo till 28 days or less if, discharged or died earlier. Weekly surveillance cultures from groin, oropharynx, rectum and blood were collected in all patients. Fungal isolates were typed based on standard microbiologic techniques. Liver enzymes were monitored. **Results:** Baseline risk factors for fungal infection in Fluconazole and Placebo groups were similar. Fungal colonization was seen in 30 infants (50%) in the placebo group and 11 infants (19%) in the Fluconazole group ($P < 0.001$). Fungal colonization at rectum, groin and oropharynx was less in fluconazole groups. Fluconazole group showed significantly lower colonizations with *Candida albicans* but not with *C. glabrata*. Invasive infection was seen in 15 (25%) infants in Placebo group and 16 (26.7%) infants in Fluconazole group ($P = 0.835$). Various non- albicans *Candida* were responsible for 96.8% cases of invasive fungal infection (*Candida glabrata* 71%, *C. parapsilosis* 14.7% and *C. tropicalis* 9.6%). No significant hepatotoxicity was noticed during Fluconazole therapy. **Conclusion:** Prophylactic fluconazole during the first four weeks of life is effective in reducing fungal colonization but not invasive infection in VLBW infants.

Key words: Antifungal Prophylaxis, *Candida*, Fluconazole, Neonate, VLBW infants

THE incidence of systemic fungal infection in newborn has been observed to range from 2.2% to 12.9% among very low birth weight (Birth weight <1500 g) infants and from 5.5% to 16.5% among those <1000 g(1-4). Study from North India demonstrated 22.8% rate of invasive fungal infection in preterm babies staying for more than one week in the Neonatal Intensive Care Unit (NICU)(5). Fungal sepsis in neonate is associated with frequent end organ dissemination (22% to 34%) and high mortality(6).

It has been shown that *Candida* species rapidly colonize the skin and mucous membranes of about 40-60% of critically ill infants and can progress to invasive infection(7,8). Colonization with *Candida* species is one of the most important predictor of invasive disease(9). Reducing fungal colonization may prevent the development of invasive fungal infection in preterm infant(10). The study was

carried out to determine if prophylactic Fluconazole decreases the incidence of *Candida* colonizations and invasive fungal infection in Very Low Birth Weight (VLBW) infants.

Subjects and Methods

This prospective, double blind, randomized controlled trial was conducted at our Level III NICU. Study Period was for one year from October 2003 to September 2004. VLBW infants admitted to Neonatal Intensive Care Unit (NICU) within first 72 hours of life were included in the study. Critically ill neonate and neonates with hepatic insufficiency as demonstrated by aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation >4 times normal values for gestational age (>244 IU/L or >152 IU/L, respectively) were excluded. Infants with first blood culture (at enrolment) growing *Candida* sp. were excluded after initial inclusion.

Randomization was done at the time of enrolment to receive either solution A or solution B (one of them being Fluconazole and other being placebo) by the shuffled sealed envelope method. Baseline data on the demographic and clinical characteristics of the infants was collected and relevant clinical data was prospectively collected throughout the course of the study on a pre-designed proforma. Presence of one or more clinical signs consistent with fungal infection (*e.g.*, temperature instability, increase in frequency of apnea, increase in oxygen requirement, ashen gray color, *etc.*) were noted.

Fungal surveillance cultures were collected on the day of randomization (day 1 to 3) and days 7, 14, 21, 28 and also as indicated by the treating physician. Surveillance cultures were collected as: rectal swab, oropharyngeal swab, skin swab from groin, umbilical swab (collected only on the day of randomization) and blood for fungal culture by venepuncture. Swabs were obtained using sterile cotton swab. Blood for fungal culture was obtained by venepuncture and collected in brain heart infusion broth; 0.5 mL blood was collected in 5 mL of broth.

Solution A or solution B was administered intravenously at a dose of 3mL/kg/day as a single dose every 72 hours till day 7 and subsequently every 24 hours till day 28 of life or till discharge from hospital whichever is earlier. Fluconazole preparation used for the study was colorless, in the strength of 1 mL = 2 mg. The placebo group received an equal volume of normal saline as it physically matched the Fluconazole solution. The drugs were given intravenously till baby reached full feeds and subsequently orally powder form (6 mg/kg) was used. Placebo group received equal amount sugar powder which was physically similar in appearance to Fluconazole powder. Drugs or Placebo were dispensed as Solution A or Solution B from pharmacy. Drug or placebo were administered by a trained senior staff nurse specifically assigned for this work.

Aspartate transaminase (AST) and Alanine transaminase (ALT) levels were measured to assess for hepato-toxicity on the day of randomization and on days of life 7, 14, 21 and 28 till the time patients

were on solutions. Any medical event not explained by the underlying disease condition of the baby was noted separately and weekly reviewed.

The administration of the study solutions (fluconazole or placebo) and the obtaining of surveillance cultures were discontinued before the determined four-week treatment period if systemic fungal infection documented, if the infant was discharged, died or transferred to another facility, or if significant hepatotoxicity was diagnosed based on biochemical monitoring. Decision on exclusion of any patient from the study and review of fungal culture pattern was done weekly. If a baby developed invasive fungal infection as determined by fungal growth in blood, solution A / B was stopped and fungal sepsis was treated with intravenous Amphotericin B.

Fungal cultures were incubated aerobically at 37°C with examination for growth at 2, 5, and 7 days after plating. Those cultures with growth were further analyzed using standard microbiologic techniques for identification of *Candida* species.

Estimation of sample size was based on the assumption that the study would have a two-sided type 1 error rate of 0.05 or less and 84% power to detect an absolute difference of 80% in the cumulative incidence of invasive fungal infection between the placebo group and the Fluconazole group after four weeks of treatment, given a pretrial incidence of invasive fungal infection of 22%. Sixty babies were enrolled in each group. Chi square test and unpaired 't' test were used to compare categorical and quantitative variables respectively. $P < 0.05$ was considered significant. Results were analyzed using SPSS software version 11.

Institutional ethics committee approved the study. An informed consent was obtained from the mother (or father) prior to enrolment.

Results

One hundred twenty one babies were randomized, to receive either Fluconazole or placebo, 1 baby was excluded after initial randomization (*Fig. 1*). Demographic characteristics and baseline risk for acquisition of fungal infection in the




Fig. 1. Enrolment in the study.

treatment group and placebo group was similar at the time of randomization (Table I).

Fresh fungal colonization occurred significantly more commonly in the placebo group as compared to the Fluconazole treated group (30% vs 8.3%, $P = 0.003$) (Table II). Fungal species—*Candida albicans*, *Candida parapsilosis* and *Candida tropicalis* colonized significantly less numbers of study subjects in Fluconazole treated group

(Table III). Colonization at groin, rectum and pharynx was significantly less over a period of 4 weeks in Fluconazole treated group (Fig. 2)

Invasive fungal infection was seen in 15 (25%) babies in placebo group and 16 (26.7%) babies in Fluconazole group ($P = 0.835$). Out of 31 patients with invasive fungal infection only 12 babies (38.7%) showed one or more clinical signs consistent with fungal infection in the preceding

TABLE I—Demographic and Clinical Characteristics of the Study Group.

	Placebo group (n = 60)	Fluconazole group (n = 60)	P
Inborn - n (%)	58 (96.66)	59 (98.33)	1.00
Birth weight (g) Mean (SD)	1280.46 (198.56)	1209.61 (241.01)	0.08
Gestational age (wks) Mean (SD)	32.51(3.14)	31.76(3.32)	0.20
Male sex (n) (%)	33 (55)	29 (48)	0.465
PROM > 24 hrs (hrs) (n) (%)	4(6.7)	7(11.7)	0.34
Intrapartum antibiotics (n) (%)	6(10)	12 (20)	0.12
Antenatal steroids			
Both doses n (%)	15 (25)	18 (30)	0.548
One dose n (%)	32 (53.33)	26 (43.33)	
Vaginal deliveries (n) (%)	44 (73.33)	45 (75)	0.83
Resuscitation at birth (n) (%)	11 (18.33)	11 (18.33)	1.00
Intravenous line (n) (%)	60 (100)	60 (100)	1
O ₂ therapy (n) (%)	34 (56.66)	38 (63.33)	0.456
CPAP (n) (%)	7 (11.66)	11 (18.33)	0.30
Intubation / Mechanical Ventilation (n) (%)	12 (20)	6 (10)	0.125
Central line (n) (%)	6 (10)	9 (15)	0.491
Parenteral nutrition (n) (%)	22(36.6)	31(51.66)	0.11
Post- natal steroids (n) (%)	11 (18.33)	6(10)	0.19
Methyl xanthines (n) (%)	20 (33.33)	25 (41.66)	0.34
H ₂ blocker use	0	0	–
Day of feed commencement Mean (SD)	2.57 (2.28)	2.16 (1.49)	0.26

week (7 in Fluconazole treated and 5 in placebo treated). Out of total 31 invasive infections, *Candida glabrata* was the predominant species infecting 22 babies (11 babies in each of placebo and Fluconazole groups). There was no difference in the pattern of fungal isolates between the placebo and Fluconazole group (*Table IV*).

Mean age at detection of fungal invasive infection was 11.2 days (SD 5.1) in placebo group and 10.9 days (SD 5.7) in Fluconazole group. ($P = 0.89$). Preceding fungal colonization before invasive infection was seen in 7 babies (46.7%) in placebo group and 4 babies (24.6%) in Fluconazole group ($P = 0.38$).

There was no difference in time taken to reach full feeds (12 days vs 12.8 days), days to regain birth

weight (10.6 days vs 10.8 days) and total duration of hospital stay (15.7 days vs 18.0 days) in the placebo and Fluconazole treated group. Most patients developed invasive fungal infection during 2nd and 3rd week postnatally and clinical signs of fungal infection were identified only in 38.7% fungemic infants. Seventeen babies died in each of Fluconazole and placebo treated groups ($P = 1$). Out of 34 babies who died, 7 babies had developed invasive fungal infection prior to death (3 in fluconazole treated and 4 in placebo treated). Fungal infection was attributed as a cause of death in 4 patients (1 in Fluconazole treated and 3 in placebo treated), however, autopsy was not performed in those patients. None of the fungemic patients developed Meningitis, Endocarditis, Osteomyelitis/ arthritis or Endophthalmitis. All fungemic patients

TABLE II—Fungal Colonization in Study Subjects over 4 weeks Duration

	Placebo group n (%)	Fluconazole group n (%)	P
<i>Colonization at enrolment</i>	12 (20)	6 (10)	0.12
Fresh colonization by day 7	12 (20)	4 (6.7)	0.058
Fresh colonization during 2nd week	4 (6.7)	1 (1.7)	0.364
Fresh colonization during 3rd week	2 (3.3)	0	0.49
Fresh colonization after day 21	0	0	—
<i>Total babies—fresh fungal colonization after enrolment (day 3 onwards)</i>	18 (30)	5 (8.3)	0.003

TABLE III—Effect of Fluconazole on Colonizing Fungal Species

	Placebo group n (%)	Fluconazole group n (%)	P
<i>Candida albicans</i>	18 (30)	7 (11.6)	0.01
<i>Candida glabrata</i>	6 (10)	2 (3.3)	0.14
<i>Candida parapsilosis</i>	5 (8.33)	0	0.02
<i>Candida krusei</i>	2 (3.33)	1 (1.66)	0.55
<i>Candida tropicalis</i>	10 (16.6)	2 (3.33)	0.01
<i>Candida keyfer</i>	1 (1.66)	1 (1.66)	—
<i>Trichosporon</i>	1 (1.66)	0	—
<i>Candida guellermondi</i>	0	1 (1.66)	—

TABLE IV—Fungal Isolates in Invasive Fungal Infection

	Placebo group n (%)	Fluconazole group n (%)	P
<i>Candida albicans</i> (n = 1)	0	1 (1.7)	
<i>Candida glabrata</i> (n = 22)	11 (18.3)	11 (18.3)	0.819
<i>Candida parapsilosis</i> (n = 5)	3 (5)	2 (3.3)	
<i>Candida tropicalis</i> (n = 3)	1 (1.7)	2 (3.3)	

started on Amphotericin B, responded well to the treatment. Fluconazole was not found to be hepatotoxic with dosage and duration used (Fig. 3).

Discussion

Our study showed significantly less number of fungal colonizations in Fluconazole treated group during the 28 days surveillance period depicting protective effect on the fungal colonization by

prophylactic fluconazole. In a similar study by Kicklighter, *et al.*(9), *Candida* colonization reduced from 46% to 15.1% ($P < 0.001$) after Fluconazole therapy. In the study by Kaufman, *et al.*(11), Fluconazole treatment decreased incidence of fungal colonization in extremely low birth weight babies from 23% to 4.9% over 6 weeks treatment period.

Fluconazole decreased fungal colonization at




Fig. 2. Sites of fungal colonization




Fig. 3. Hepatic enzymes over 4 weeks treatment period

rectal, groin and oropharyngeal sites, that is Fluconazole was effective even at sites other than gastrointestinal tract, an advantage over use of oral local antifungals like Nystatin. Similar results were observed by Kaufman, *et al.*, where Fluconazole

decreased fungal colonization at skin, stool and nasopharynx(11).

In the present study various “non-albicans *Candida*’ species were predominant species causing colonization (56% cases). In the study by Baley

What is Already Known

- Fungi are common cause of morbidity and mortality in VLBW neonates.

What this Study Adds

- Non-albicans candida are becoming prominent fungal species causing colonizations and invasive infections in VLBW neonates. Routine use of prophylactic fluconazole in VLBW neonates warrants caution.

et al. and Kicklighter, *et al.*, colonizations by “non albicans *Candida*” was 39% and 47% respectively(8,9). Thus when compared with previous studies, there is higher rate of colonization with non-albicans *Candida* in the present study.

Our study demonstrated high incidence of invasive fungal infection of 25.8% in VLBW babies(1-4) with predominant fungal pathogens being non albicans *Candida* responsible for 96.8% cases. Study by Narang, *et al.* in the year 1999, from North India showed 22.8% incidence of invasive fungal infection in preterm neonates(5). Another study from the same institution showed that 56.5% fungal isolates from neonatal fungal sepsis were non-albicans candida (*C. tropicalis* in 21.7%, *C. guilliermondii* in 13%, *C. parapsilosis* in 13% and *C. krusei* in 8.7%(14). In a previous study from our institution out of total 30 neonatal invasive fungal infections 46.7% were caused by non-albicans candida. (*C. tropicalis* (23.3%) and *C. krusei* (23.3%)(15). In the study by Kaufman, *et al.*(11) the incidence of invasive fungal infection was 20% in the placebo group and out of 10 fungal isolates 50% were non albicans candida (*Candida parapsilosis* 3, *Candida glabrata* 1 and *Candida dubliniensis* 1).

C. krusei and *C. glabrata* are species with intrinsic resistance to Fluconazole(16) *C.tropicalis* and *C. parapsilosis* tend to be less susceptible to azoles, particularly Fluconazole than *C. albicans*(12). Clearly, present study highlights the fact that more and more cases of non-albicans candida, which are resistant to fluconazole are being isolated in our NICUs.

Moreover, various *Candida* species which are resistant to fluconazole are now being reported. In a study by Narang, *et al.*(17), out of total 23 cases

of fungal sepsis four isolates *i.e.*,17.7% (*C. parapsilosis* = 2, *C. albicans* = 1 and *C. guilliermondii* = 1) were resistant to Fluconazole. Study from our institution showed 18.7% *C. albicans* isolates from neonates, resistant to Fluconazole(14). Development of resistance in *Candida parapsilosis* associated with long term Fluconazole prophylaxis has been demonstrated in an animal model(18). In humans, development of Fluconazole resistance in *C. albicans* has been demonstrated in adult HIV positive women on Fluconazole prophylaxis(19,13,20).

Fluconazole is used in our NICU since last six years, which could be the reason for high incidence of non-albicans *Candida* species, which are less susceptible to Fluconazole. Similar timing of presentation of invasive fungal infection in the Fluconazole and placebo group highlights the fact that Fluconazole was not effective in preventing invasive fungal infection in the present study. There may be other significant factors apart from superficial colonization that contribute to fungal sepsis; as in this study, a reduction of fungal colonization by prophylactic fluconazole did not bring down rate of invasive fungal infection(9).

We could not screen urinary tract for fungal infection, as it necessitates suprapubic puncture. It is likely that some cases of isolated urinary tract infection or colonization were missed. We could not test for fungal resistance to Fluconazole. Despite these two limitations, we think that routine use of prophylactic Fluconazole in very low birth weight is not recommended. Periodic review of fungal isolates is mandatory to decide unit policy on antifungal treatment. Future research should be directed to identify other risk factors for invasive

fungal infection and various interventions to limit those infections.

Acknowledgement

KEM Hospital Staff Society, Mumbai for financially supporting the project and Dr Nilima Kshirsagar, Dean, Seth G S Medical College and KEM Hospital, for permitting to publish this article.

Contributors: TP supervised sample collections and drug administration, collected and analysed the data, drafted the manuscript. RN conceptualized the study, critically revised the manuscript, will act as its guarantor. All authors contributed in development of study protocol. SR participated in data collection. CP & KB carried out the fungal tests, RU & PM supervised the study.

Competing interests: None.

Funding: The research project was supported by a research grant from KEM Hospital Staff Society, Mumbai.

REFERENCES

1. Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, *et al.* Late onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network. *J Pediatr* 1996; 129: 63-71.
2. Chapman RL, Roger GF. Invasive Neonatal Candidiasis: An overview. *Semin Perinatol* 2003; 27: 352-356.
3. Fanaroff AA, Korones SB, Wright LL, Verter J, Poland RL, Bauer CR, *et al.* Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. *Pediatr Infect Dis J* 1988; 17: 593-598.
4. Kossoff EH, Buescher ES, Karłowicz MG. Candidemia in a neonatal intensive care unit: Trends during fifteen years and clinical features of 111 cases. *Pediatr Infect Dis J* 1998; 17: 504-508.
5. Singh K, Chakrabarti A, Narang A, Gopalan S. Yeast colonisation and invasive fungal infection in preterm neonates in a tertiary care centre. *Indian J Med Res* 1999; 110: 169-173.
6. Kaufman D. Strategies for prevention of neonatal invasive candidiasis. *Semin Perinatol* 2003; 5: 414 - 428.
7. Baley JE. Neonatal candidiasis: the current challenge. *Clin Perinatol* 1991; 18: 263-280.
8. Baley JE, Kleigman RM, Boxerbaum B, Fanaroff AA. Fungal colonization in the very low birth weight infants. *Pediatrics* 1986; 78: 225-232.
9. Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB. Fluconazole for prophylaxis against Candidal rectal colonization in the very low birth weight infant. *Pediatrics* 2001; 107: 293-298.
10. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, *et al.* Practice guidelines for the treatment of candidiasis. *Infectious Diseases Society of America. Clin Infect Dis J* 2000; 30: 662-678.
11. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG, *et al.* Fluconazole prophylaxis against fungal colonization and infection in preterm infants. *N Engl J Med* 2001; 345: 1660-1666.
12. Chander J. Candidiasis. *In: Chander J, ed. Textbook of Medical Mycology*, 2nd edn, New Delhi: Mehta Publishers 2002; p 212-230.
13. Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snyderman DR, *et al.* The changing face of care in candidemia: emergence of non-Candida albicans species and antifungal resistance. *Am J Med* 1996; 100: 617-623.
14. Narayanan S. Candidiasis with special reference to immunocompromised patients. Dissertation submitted for MD (Microbiology) at the University of Mumbai, Jan 2000.
15. Narang A, Agrawal PB, Chakrabarti A, Kumar P. Epidemiology of systemic candidiasis in a tertiary care neonatal unit. *J Trop Pediatr*. 1998; 44: 104-108.
16. Bliss JM, Wellington M, Gigliotti F. Antifungal pharmacotherapy for neonatal candidiasis. *Semin Perinatol* 2003; 27: 365-374.
17. Narang A, Agrawal P, Chakraborti A, Kumar P. Fluconazole in the management of neonatal systemic candidiasis *Indian Pediatr* 1996; 33: 823-826.
18. Yoder BA. Resistant Candida parapsilosis associated with long term Fluconazole prophylaxis in an animal model. *Pediatr Infect Dis J* 2004; 23: 687-868.
19. Vazquez JA, Peng G, Sobel JD, Steele-Moore L, Schuman P, Holloway W. Evolution of antifungal susceptibility among *Candida* species isolates recovered from human immunodeficiency virus-infected women receiving Fluconazole prophylaxis. *Clin Infect Dis* 2001; 33: 1069-1075.
20. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibility of Candida species and distribution of species recovered from blood cultures over a 5-year period. *Antimicrob Agents Chemother* 1994; 38: 1422-1424.